Compared with NSCLC patients without targetable oncogenes, patients with EGFR 20ins NSCLC have better outcomes with platinum chemotherapy but derive less benefit from ICIs, as explained by lower levels of TMB and PD-L1 expression (20). Here, EGFR is linked to non-small cell lung carcinoma.